MedPath

NEXGEN PHARMA, INC.

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

2

Active:0
Completed:2

Trial Phases

1 Phases

Phase 1:2

Drug Approvals

13

FDA:10
PHILIPPINES:3

Drug Approvals

Ursodiol 200 mg

Approval Date
May 15, 2020
FDA

Nabumetone 500 mg

Approval Date
Sep 27, 2019
FDA

Chenodiol

Approval Date
Sep 6, 2019
FDA

Glycopyrrolate

Approval Date
Sep 6, 2019
FDA

Butalbital, Acetaminophen, and Caffeine

Approval Date
Sep 6, 2019
FDA

Mecamylamine Hydrochloride

Approval Date
Sep 4, 2019
FDA

Butalbital, Acetaminophen, and Caffeine

Approval Date
Sep 3, 2019
FDA

Butalbital and Acetaminophen

Approval Date
Aug 22, 2019
FDA

Polyethylene Glycol 3350

Approval Date
Aug 10, 2011
FDA

Polyethylene Glycol 3350

Approval Date
Aug 10, 2011
FDA

Clinical Trials

Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials

Phase 1
2 (100.0%)

Codeine Phosphate/Guaifenesin ER Tablet 30 mg/600 mg Steady State Clinical Study

First Posted Date
2015-10-08
Last Posted Date
2017-03-29
Lead Sponsor
Nexgen Pharma, Inc
Target Recruit Count
38
Registration Number
NCT02572375
Locations
🇯🇴

Pharmaceutical Research Unit, Amman, Jordan

Single Dose Trial of Extended Release Combination Tablet Codeine and Guaifenesin

Phase 1
Completed
Conditions
Cough
Interventions
Drug: ER Tablet under Fasted Conditions
Drug: ER Tablet under Fed Conditions
Drug: IR Tablet under Fasted conditions
First Posted Date
2014-06-06
Last Posted Date
2015-04-15
Lead Sponsor
Nexgen Pharma, Inc
Target Recruit Count
26
Registration Number
NCT02157649
Locations
🇯🇴

Pharmaceutical Research Unit, Amman, Jordan

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.